CRISPR Therapeutics Licenses Cell Engineering Platform From MaxCyte – GenomeWeb
Proactive Investors UK |
CRISPR Therapeutics Licenses Cell Engineering Platform From MaxCyte
GenomeWeb NEW YORK (GenomeWeb) – CRISPR Therapeutics and Casebia Therapeutics, its joint venture with Bayer, have signed a licensing deal for a cell transfection platform from MaxCyte. Under the terms of the agreement, CRISPR Therapeutics and Casebia will … CRISPR Therapeutics and Casebia Therapeutics Announce … CRISPR Therapeutics and JV with Bayer nab non-exclusive rights to MaxCyte's cell engineering platform MaxCyte Inks License Deal With CRISPR Therapeutics And Bayer … |
